Related Experiment Video
Updated: Feb 21, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
MYSM1/2A-DUB is an epigenetic regulator in human melanoma and contributes to tumor cell growth
Christina Wilms1, Carsten M Kroeger1, Adelheid V Hainzl1
1Department of Dermatology and Allergic Diseases, Ulm University, 89081 Ulm, Germany.
Abstract:
Histone modifying enzymes, such as histone deacetylases (HDACs) and polycomb repressive complex (PRC) components, have been implicated in regulating tumor growth, epithelial-mesenchymal transition, tumor stem cell maintenance, or repression of tumor suppressor genes - and may be promising targets for combination therapies of melanoma and other cancers. According to recent findings, the histone H2A deubiquitinase 2A-DUB/Mysm1 interacts with the p53-axis in hematopoiesis and tissue differentiation in mice, in part by modulating DNA-damage responses in stem cell and progenitor compartments. Based on the identification of alterations in skin pigmentation and melanocyte specification in Mysm1-deficient mice, we hypothesized that MYSM1 may be involved in melanoma formation. In human melanoma samples, expression of MYSM1 was increased compared with normal skin melanocytes and nevi and co-localized with melanocyte markers such as Melan-A and c-KIT. Similarly, in melanoma cell lines A375 and SK-MEL-28 and in murine skin, expression of the deubiquitinase was detectable at the mRNA and protein level that was inducible by growth factor signals and UVB exposure, respectively. Upon stable silencing of MYSM1 in A375 and SK-MEL-28 melanoma cells by lentivirally-mediated shRNA expression, survival and proliferation were significantly reduced in five MYSM1 shRNA cell lines analyzed compared with control cells. In addition, MYSM1-silenced melanoma cells proliferated less well in softagar assays. In context with our finding that MYSM1 bound to the c-MET promoter region in close vicinity to PAX3 in melanoma cells, our data indicate that MYSM1 is an epigenetic regulator of melanoma growth and potentially promising new target for tumor therapy.
Insights
The histone H2A deubiquitinase MYSM1 is upregulated in melanoma and drives tumor growth by epigenetically regulating genes like c-MET. Silencing MYSM1 reduces melanoma cell survival and proliferation, identifying it as a potential therapeutic target.
Area of Science:
- Epigenetics
- Cancer Biology
- Molecular Oncology
Background:
- Histone modifying enzymes, including histone deacetylases (HDACs) and polycomb repressive complex (PRC) components, are crucial in cancer development.
- The histone H2A deubiquitinase 2A-DUB/Mysm1 (MYSM1) plays a role in hematopoiesis and tissue differentiation by influencing DNA-damage responses.
- Alterations in MYSM1 have been observed in skin pigmentation and melanocyte specification, suggesting a potential role in melanoma.
Purpose of the Study:
- To investigate the role of MYSM1 in melanoma formation and progression.
- To determine if MYSM1 expression is altered in human melanoma samples and cell lines.
- To evaluate the therapeutic potential of targeting MYSM1 in melanoma.
Main Methods:
- Analysis of MYSM1 expression in human melanoma samples, nevi, and normal skin.
- Detection of MYSM1 mRNA and protein levels in melanoma cell lines and murine skin.
- Induction of MYSM1 expression by growth factors and UVB exposure.
- Stable silencing of MYSM1 using lentivirally-mediated shRNA in melanoma cells.
- Assessment of cell survival, proliferation, and soft agar colony formation in MYSM1-silenced cells.
- Chromatin immunoprecipitation (ChIP) to identify MYSM1 binding sites, such as the c-MET promoter.
Main Results:
- MYSM1 expression is significantly increased in human melanoma tissues compared to normal skin and nevi.
- MYSM1 is expressed at mRNA and protein levels in melanoma cell lines and murine skin, inducible by growth factors and UVB.
- Silencing MYSM1 in melanoma cells markedly reduces their survival and proliferation.
- MYSM1-silenced cells exhibit reduced proliferation in soft agar assays.
- MYSM1 was found to bind to the c-MET promoter region in melanoma cells.
Conclusions:
- MYSM1 is an epigenetic regulator involved in melanoma cell growth and survival.
- Increased MYSM1 expression is a feature of melanoma.
- MYSM1 represents a promising novel therapeutic target for melanoma treatment.
Related Concept Videos
Abnormal Proliferation
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Induced Pluripotent Stem Cells
Somatic...
Mitogens and the Cell Cycle

